GU Cancers 2025 | The emerging role of neoadjuvant durvalumab in urothelial carcinoma
Nadine Houede, MD, Centre Hospitalier Universitaire de Nîmes, Nîmes, France, discusses the role of neoadjuvant checkpoint inhibitors in urothelial carcinoma, highlighting durvalumab’s efficacy in comparison to other immunotherapies. Durvalumab has shown significant benefits in patients with locally advanced urothelial carcinoma, particularly in those with high-risk features. However, more research is needed in upper tract cancers, due to differences in genetic alterations. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
What is the data for immunotherapy? We have some data for immunotherapy in bladder cancer. You saw this morning the nivolumab results, which is similar, but only for bladder cancer. It’s very important to have a specific design for upper tract trials, because they don’t have the same embryological origin. They don’t have the same alterations in genes...
What is the data for immunotherapy? We have some data for immunotherapy in bladder cancer. You saw this morning the nivolumab results, which is similar, but only for bladder cancer. It’s very important to have a specific design for upper tract trials, because they don’t have the same embryological origin. They don’t have the same alterations in genes. So it’s very important to have a specific design. We don’t have much data regarding the response to immunotherapy for this specific treatment. So we decided to go further with durvalumab. We know that we have some PD-L1 and PD-1 inhibitors. So we are right now working in the lab to define if there are some differences between this treatment and different antibodies. But it will be another paper.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
